Breye Therapeutics announced the successful completion of its phase 1b clinical trial of an oral therapy, danegaptide, for early treatment of non-proliferative diabetic retinopathy (NPDR) and ...

Dr. Gonzalez shares 126-week topline results from the REMAIN study, assessing optogenetic therapy MCO-010 (Nanoscope Therapeutics). Ahead of the Clinical Trials at the Summit (CTS) meeting in Las ...

Clinical-stage biotechnology company PYC Therapeutics recently held a type B meeting with the US Food and Drug Administration (FDA) to discuss requirements for a new drug application (NDA) for the ...

One of my favorite components of my career has been building a leading clinical trial program at our practice. Clinical science has allowed me to offer cutting-edge treatments in my community while ...

The Dextenza insert provides an additional measure of safety should patients be nonadherent to instructions for postoperative drops. We have all seen patients at a postoperative appointment without ...

June 2nd 2025. Two FDA-approved geographic atrophy treatments show significant patient dropout, with 45% discontinuation by 18 months, driven by baseline vision, CNV, and lack of immediate visual ...

Anat Loewenstein, MD, spoke with Modern Retina about her presentation of AXPAXLI trial results and upcoming trials for this potential treatment, which she gave at Clinical Trials at the Summit meeting ...

More than 300 patients have been randomized in the SOL-1 Phase 3 trial for OTX-TKI (AXPAXLI, axitinib intravitreal implant). The trial is expected to close randomization in early December 2024. This ...

Mary Elizabeth Hartnett, MD, FACS, discussed the impact of blindness and vision loss on women in the United States. Keep your retina practice on the forefront—subscribe for expert analysis and ...

Theodore Leng, MD, MS, sat down to discuss his presentation on the FARETINA-DME Study at the American Society of Retina Specialists meeting held in Stockholm, Sweden.

Scientists enhance eye imaging with AI, achieving high-resolution views of retinal cells, potentially revolutionizing disease detection and monitoring in clinics. The National Institutes of Health ...

Although my practice is primarily an anterior segment practice, the care of patients with age-related macular degeneration (AMD) is something I have always followed closely. AMD is the leading cause ...